Another interesting small molecule, with no previously reported binding to DHFR

Go down

Another interesting small molecule, with no previously reported binding to DHFR

Post  jy9202 on Wed Jul 02, 2014 6:56 am

Another study identified potential drug targets for three neurological [You must be registered and logged in to see this link.] disorders Alzheimers disease, Parkinsons disease and Schizo phrenia. This study involved the prediction of candidate genes using the ToppGene and ToppNet prediction systems. The repositioning tools could be used as an initial screening tool for potential drugs which can be used for further evaluation. It is important to note that not all repositioning opportunities will be successful as there are always some limitations. Conclusion There is a need to develop new approaches for the iden tification of therapeutic targets to accelerate the process of therapeutic drug discovery which has not kept pace with discoveries in genetics. In this study, we integrated detailed drug data with predicted candidate genes for seven complex diseases.

We found 29% of the predicted candidate genes could serve as novel therapeutic targets and 29% of the extracted drugs are potential novel ther apeutics for at least one of the seven complex diseases considered in our study. We have utilized both FDA approved drugs and [You must be registered and logged in to see this link.] drugs in clinical trials. Further investigation is required to verify the action of these drugs. This study enables efficient identification of pos sible novel therapeutic targets and alternative indications for existing therapeutics. Hence, these drugs may be repositioned against seven phenotypes of interest, quickly taking advantage of already done work in phar maceutics to translate ground breaking results in genet ics to clinical treatments.

Gentrepid, thus can be utilized as a drug screening tool to save time and money [You must be registered and logged in to see this link.] spent on the initial stages of drug discovery. RCC is one of the most common malignant tumors in urology. RCC accounts for 2 3% of all malignant tumors in adults, afflicts about 209,000 people, and causes 102,000 deaths per year worldwide. The incidence and mortality rate of RCC have increased over the past sev eral years. RCC is classified into five major sub types, clear cell, papillary, chromophobe, collecting duct and unclassified RCC. Many renal masses remain asymptom atic and nonpalpable until the late stages of the disease. Curative nephrectomy is the first treatment choice for RCC. However, metastatic disease recurs in a third of these patients. Still, About 30% of patients already have metastasis at the time of diagnosis.

Although several promising biomarkers for RCC such as Carbonic anhy drase IX, B7 H1 and P53 have been investigated, none have been validated. RCC is resistant to chemo therapy, radiotherapy and immunotherapy. Although several targeted therapies, such as multitargeted tyro sine kinase inhibitors and Temsirolimus, which target the VHL HIF VEGF and or mTOR pathways, have been approved for the treatment of advanced RCC, complete responses are rare and resistance ultim ately will occur after a few months or a few years. Thus, the identification and application of novel thera peutic targets for RCC are urgently needed. Epithelial and endothelial tyrosine kinase, also known as bone marrow X kinase, is one member of the Tec family of non receptor tyrosine kinases. ETK contains a PH domain, a SH3 domain, a SH2 do main from the amino terminus, and the kinase domain in the carboxyl terminus.


Posts : 509
Join date : 2013-12-18

View user profile

Back to top Go down

Back to top

Permissions in this forum:
You cannot reply to topics in this forum